Kore Regenerative Medicine: How to Evaluate Any Clinic’s Quality Standards in 2026
Introduction: Why Searching for Kore Regenerative Medicine Reveals a Bigger Question
Patients and providers who search for Kore Regenerative Medicine are typically researching a specific clinic in Golden, Colorado, led by Dr. Jordanna Quinn, D.O., a board-certified Physical Medicine and Rehabilitation physician with more than a decade of regenerative medicine experience. It is a reasonable starting point. But that search reveals a far more important question that almost no one asks: in a market with an estimated 2,750 stem cell clinics operating across the United States, how does anyone distinguish a genuinely compliant, high-quality regenerative medicine organization from one that is not?
The stakes are not theoretical. Patients have suffered blindness, tumor growth, neurological harm, and life-threatening infections from unregulated injections and contaminated products. Evaluating quality is a patient safety imperative, not a consumer preference. This article provides a practical, infrastructure-focused framework for evaluating any regenerative medicine clinic or biologics supplier, addressing the compliance questions most content ignores. With the global regenerative medicine market projected to grow from roughly $58.40 billion in 2026 to $360.84 billion by 2034, the need for real quality standards has never been more urgent.
The State of Regenerative Medicine in 2026: Rapid Growth, Uneven Standards
The sector is expanding at a compound annual growth rate exceeding 25 percent, with specialty clinics like Kore representing the fastest-growing end-user segment, projected to grow between 21 and 25 percent annually. That explosive growth has outpaced standardization. The pivotal shift of the past 24 months has been toward protocol standardization, because earlier regenerative medicine produced wildly inconsistent outcomes when the same therapy was administered differently at different clinics.
The information problem is equally severe. A 2020 study found that 96 percent of stem cell clinic websites displayed at least one misstatement, averaging four to five misstatements per site. The legal landscape, however, has clarified. In October 2025, the U.S. Supreme Court declined to reconsider a decision confirming the FDA’s regulatory authority over unproven stem cell therapies. The FDA’s 2026 guidance updates clarify, but do not ban, stem cell therapy, making it easier to identify compliant versus non-compliant clinics, but only for those who know what to look for. The core tension remains: most patients, and even many providers, lack the framework to ask the right questions.
What Kore Regenerative Medicine Gets Right: A Baseline for Comparison
Founded in April 2019 and located in Golden, Colorado, Kore Regenerative Medicine is led by Dr. Jordanna Quinn, D.O., M.S., board-certified by the American Osteopathic Board of Physical Medicine and Rehabilitation. Her credentials offer a meaningful baseline: specialty training in Regenerative Medicine, Functional Medicine, Anti-Aging Medicine, and Psychedelic Medicine, plus more than a decade working with autologous and allogeneic stem cells.
Professional affiliations signal credentialing seriousness, including a listing in the A4M (American Academy of Anti-Aging Medicine) provider directory and affiliation with the Interventional Orthobiologics Foundation (IOF). Kore’s service portfolio is representative of a modern integrative clinic: ultrasound-guided PRP and stem cell injections, functional medicine evaluations, bioidentical hormone therapy, IV nutrient infusions, ketamine-assisted therapy, and regenerative aesthetics. Kore serves as a reference point, not a target, to illustrate what a credentialed clinic looks like on the surface, before the deeper infrastructure questions that even credentialed clinics must answer.
The Compliance Framework Every Regenerative Medicine Clinic Should Meet
The FDA’s risk-based regulatory framework under 21 CFR Part 1271 is the foundational compliance structure for all human cells, tissues, and cellular and tissue-based products (HCT/Ps). It defines the legal and safety boundaries within which any clinic offering allogeneic biologics must operate. Non-compliance is not a technicality; it is a patient safety risk. The following five pillars form the practical evaluation framework: HCT/P classification, donor eligibility screening, cGMP/CGTP manufacturing, third-party sterility testing, and lot traceability. The absence of this information from a clinic or supplier is itself a red flag.
Pillar 1: Understanding HCT/P Classification, 361 vs. 351 Products
Under 21 CFR Part 1271, products fall into two lanes. A “361 HCT/P” is minimally manipulated, intended for homologous use, and requires no premarket approval. A “351 product” is higher-risk and requires a Biologics License Application or NDA. Many existing orthobiologics, including PRP and BMAC, fall under Section 361 as minimally manipulated products, while more complex allogeneic cell therapies face higher scrutiny. The 21st Century Cures Act also created the Regenerative Medicine Advanced Therapy (RMAT) pathway; as of September 2025, the FDA had received nearly 370 designation requests, approved 184, and approved 13 RMAT-designated products for marketing.
Ask: “Is this product classified as a 361 HCT/P or a 351 product, and can you provide documentation?”
Pillar 2: Donor Eligibility Screening, The First Line of Patient Safety
21 CFR Part 1271 requires all HCT/P establishments to screen and test donors for relevant communicable disease agents and diseases before tissue is distributed. Comprehensive screening includes medical history review, physical examination records, and laboratory testing for HIV, hepatitis B and C, syphilis, and other pathogens. This matters most for allogeneic products derived from a donor other than the patient. Autologous procedures (PRP, BMAC) use the patient’s own cells, while allogeneic biologics (exosomes, amniotic and umbilical cord products) carry documented transmission risk.
Ask: “Can you provide the donor eligibility determination documentation for the allogeneic products used in my treatment?”
Pillar 3: cGMP and CGTP Manufacturing Standards
Current Good Tissue Practice (CGTP) governs HCT/P manufacturing under 21 CFR Part 1271, requiring an FDA-registered establishment, standard operating procedures, environmental monitoring, personnel training, equipment qualification, and process validation. Current Good Manufacturing Practice (cGMP) cleanroom production involves ISO-classified cleanrooms, particulate and microbial monitoring, gowning protocols, and documented batch records. Many gray-zone suppliers do not manufacture in FDA-registered, CGTP-compliant facilities. AATB (American Association of Tissue Banks) accreditation is an additional voluntary standard signaling rigor.
Ask: “Is your manufacturing facility FDA-registered under 21 CFR Part 1271, and can you provide your establishment registration number?”
Pillar 4: Third-Party Sterility Testing
Independent sterility testing is superior to in-house quality control because outside laboratories have no financial incentive to pass a product that should fail. Compliant biologics should undergo sterility testing (USP <71>), mycoplasma testing, endotoxin and pyrogen testing, and identity and potency assays where applicable. Contaminated products have caused life-threatening infections, making this non-negotiable. A certificate of analysis (COA) documents that a specific lot passed all required tests.
Ask: “Can you provide a certificate of analysis from an independent, accredited laboratory for the specific lot used in my treatment?”
Pillar 5: Lot Traceability
Lot traceability is the ability to track any HCT/P from the donor through manufacturing, distribution, and administration to the recipient, and back again if a safety issue arises. 21 CFR Part 1271 requires establishments to maintain records that allow tracking from receipt through distribution or disposition. If a defective product is identified, traceability enables rapid notification of all affected patients. Gray-zone suppliers often cannot provide lot-level documentation.
Ask: “What is the lot number, and can you provide the full chain of custody from the tissue bank to this clinic?”
The Supplier Side: Questions Providers Must Ask Their Biologics Distributors
Even a credentialed, well-intentioned clinic can unknowingly use non-compliant biologics if its supplier operates in the gray zone. Most regenerative medicine content focuses on physician credentials, but the quality of the biologics supply chain is equally critical. Providers should require: FDA establishment registration verification, CGTP compliance documentation, AATB or equivalent accreditation, third-party COAs for each lot, donor eligibility records, adverse event reporting procedures, and product liability insurance.
The financial stakes sharpen this responsibility. Most regenerative procedures are not covered by commercial insurance or Medicare in 2026, so patients pay out of pocket, making trust, transparency, and outcomes documentation critical differentiators. A provider’s reputation and legal liability are directly tied to the compliance status of their supplier. Due diligence is not optional.
What Integrated Compliance Infrastructure Looks Like in Practice
Having compliant products is not the same as running a compliant program. True compliance extends beyond sourcing to clinical protocols, consent workflows, adverse event monitoring, and outcomes documentation. A complete infrastructure includes product sourcing standards, safety and risk profiling, regulatory pathway alignment, clinical protocol support, informed consent documentation, real-world outcomes tracking, and continuing education.
As Mayo Clinic research has noted, underlying fundamental science must be responsibly translated into robust, transparent, evidence-based, and guidelines-sanctioned best practices, supported by regulatory oversight, quality control, and standardized compliance. Emerging regulatory complexity, including state legislation and RMAT pathway updates, makes integrated infrastructure more valuable, not less. AI-powered tools now embed real-time safety profiling, automated documentation, outcomes tracking, and regulatory alignment directly into clinical workflows.
How Matrix Biologics Sets the Infrastructure Benchmark
Matrix Biologics is a provider-first regenerative medicine distribution company that has built this compliance infrastructure into its core platform. Its Matrix-Accredited sourcing standards apply expert-led, compliance-driven validation that verifies FDA registration, CGTP compliance, donor eligibility documentation, third-party sterility testing, and lot traceability before any product enters the distribution network. Each of the five pillars above maps directly to this process.
The Integrated Safety Intelligence™ (ISI) platform uses FDA-approved AI software as the digital safety and compliance backbone of regenerative programs, covering safety and risk profiling, regulatory pathway alignment, clinical protocols, consent workflow management, and real-world outcomes tracking. Programs are supported by clinical pharmacists and compliance experts, including CEO and Founder Dr. Suzanne Robertson, Pharm.D., who brings nearly two decades of healthcare leadership experience. CME-accredited education programs reinforce a commitment to ongoing provider knowledge, not just product sales.
Red Flags: Signs a Clinic or Supplier May Be Operating in the Gray Zone
For patients evaluating clinics: inability to name the biologics supplier, no COA available, no FDA establishment registration number, marketing claims of “FDA-approved stem cell therapy” (a common misstatement), no adverse event reporting protocol, and no outcomes tracking.
For providers evaluating suppliers: no FDA establishment registration, no CGTP documentation, no third-party sterility COAs, no donor eligibility records, no lot traceability system, and no liability insurance documentation.
The finding that 96 percent of clinic websites contained misstatements reflects an information quality problem that also exists at the supplier level. As the American Society of Gene & Cell Therapy warns, some unethical providers offer cell therapy products that have not received required regulatory review, are offered illegally, have not been tested for effectiveness, and may be dangerous. The absence of documentation is not a bureaucratic inconvenience; it is a direct indicator of whether a clinic prioritizes evidence-informed care over marketing.
Conclusion: The Standard Has Been Set, Now It’s Time to Meet It
In a rapidly growing market with documented safety risks and regulatory complexity, the quality of a regenerative medicine program is determined not just by physician credentials but by the entire infrastructure: from biologics sourcing to compliance documentation to outcomes tracking. The five pillars (HCT/P classification, donor eligibility screening, cGMP/CGTP manufacturing, third-party sterility testing, and lot traceability) give any patient or provider a practical evaluation framework.
Clinics like Kore Regenerative Medicine, with credentialed leadership and professional affiliations, represent the serious, patient-focused organizations that benefit most from partnering with equally rigorous suppliers and compliance infrastructure. The 2026 environment, with updated FDA guidance, the Supreme Court’s affirmation of FDA authority, and the maturing RMAT pathway, marks a moment of clarity. The organizations that will lead the next decade are those that treat compliance not as a burden but as a competitive advantage and a patient safety imperative.
Ready to Build a Regenerative Program on a Foundation That Meets the Standard?
If a clinic, provider network, or individual practitioner is offering regenerative therapies, the compliance infrastructure described here is not aspirational. It is achievable with the right partner. Matrix Biologics’ Matrix-Accredited sourcing, Integrated Safety Intelligence™ platform, and clinical pharmacist oversight can serve as the compliance backbone of a regenerative program, removing the burden of supplier vetting, regulatory navigation, and documentation management so providers can focus on patient outcomes.
Contact Matrix Biologics to request a provider consultation, review the Matrix-Accredited product catalog, or explore how the ISI platform integrates with existing clinical workflows.
Matrix Biologics
Raintree Corporate Center, 15333 N. Pima Road, Suite #305, Scottsdale, AZ 85260
Phone: 602-480-0486
matrixbiologics.com
